<DOC>
	<DOCNO>NCT02321397</DOCNO>
	<brief_summary>This study aim demonstrate equivalence combination low strength OXN PR tablet ( OXN PR LST ) single high strength OXN PR tablet ( OXN PR HST ) take overall daily dose .</brief_summary>
	<brief_title>To Demonstrate Equivalence Analgesic Efficacy &amp; Bowel Function Between OXN PR Higher Dose &amp; Lower Dose Tablet Strengths Subjects With Non-cancer Cancer Pain</brief_title>
	<detailed_description>Study OXN3508 multicenter double-blind , double-dummy , randomised , cross-over , 2-period , phase III study male female subject severe non-malignant malignant pain require around-the-clock opioid therapy daily dose 120/60 mg 160/80 mg oxycodone/naloxone prolong release ( OXN PR ) .</detailed_description>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Inclusion Criteria Subjects receive WHO step III opioid analgesic medication treatment nonmalignant malignant pain . Documented history nonmalignant malignant pain require aroundtheclock opioid therapy Exclusion Criteria Females pregnant lactating . Subjects evidence significant structural abnormality gastrointestinal tract . Subjects evidence impair liver/kidney function upon entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>oxycodone naloxone combination</keyword>
	<keyword>severe chronic non-malignant pain</keyword>
	<keyword>Malignant non-malignant pain require around-the clock opioid therapy</keyword>
</DOC>